Exciting week at the World Vaccine Congress in Washington, D.C.! 🧬 The LineaRx team is proud to showcase our rapid enzymatic DNA production platform — powering the next generation of mRNA and DNA-based therapies. We’re grateful for the opportunity to connect with innovators across the vaccine ecosystem and share how our technology is accelerating therapeutic breakthroughs. Our enzymatic manufacturing platform is capable of producing DNA quantities necessary to support a nucleic acid-based therapy across its entire product lifecycle. With its compact benchtop manufacturing equipment, LineaRx can rapidly scale to meet virtually any demand, from the µg to g scale. Stop by Booth 479 or visit www.linearxdna.com to learn more. #WVC2025 #SyntheticDNA #mRNA #EnzymaticDNA #VaccineInnovation #LineaRx #Biotech
About us
We have two core business segments, one focused on supply chain authentication across multiple industries. The second is focused on large scale linear DNA production for diagnostics and vaccines.
- Website
-
http://www.adnas.com
External link for Applied DNA Sciences
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Type
- Public Company
- Specialties
- Textile Supply Chain Protection, Cash-In-Transit Protection, Asset Marking, Crime Prevention, large-scale DNA production, authentication technology, Cannabis, Personal Care, Fertilizer, Printing and Packaging, and COVID-19 Solutions
Locations
-
Primary
Get directions
-
Get directions
50 Health Sciences Dr
Stony Brook, New York 11790, US
Employees at Applied DNA Sciences
-
Sanjay M. Hurry
Executive Director, Investor Relations and Corporate Communications, Applied DNA Sciences, Inc. (NASDAQ: APDN)
-
Judy Murrah
President, Chief Operating Officer at Applied DNA Sciences
-
Brian Viscount
Vice President Biopharma and DNA production at Applied DNA Sciences
-
Heather Berry
Updates
-
At LineaRx, Inc., we are committed to supporting secure, domestic supply chains for advanced genetic medicines. LineaRx has completed an initiative to ensure the supply of all critical inputs for our LineaDNA™ & LineaIVT™ platforms from U.S. suppliers. With the current tariff environment, we are positioned to help biopharma reshore their development and manufacturing of genetic medicines to the U.S. as the largest PCR-based cell-free DNA producer in the U.S. and able to deliver GMP-grade product. Read the full release: https://lnkd.in/eyPzJnHK #LineaRx #SyntheticDNA #Reshoring #Biotech #MadeInUSA #LineaDNA #LineaIVT #GeneticMedicines
-
LineaRx, Inc. is showcasing its Linea™ IVT and Linea™ DNA platforms at the World Vaccine Congress, April 21-24, at the Walter E. Washington Convention Center, Washington, D.C. Visit us at Booth 479 to explore our innovative solutions. Further information is available at lineadna.com. #syntheticbiology #EnzymaticDNAProduction #PCR #mRNA #GeneticMedicine #NucleicAcidBasedTherapies #DNAInnovation #CellFreeDNAProduction #SyntheticDNA #BiotechInnovation
-
-
Applied DNA Sciences received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Nasdaq determined that for 16 consecutive business days, from March 14 through April 4, 2025, the closing bid price of the Company’s common stock was $1.00 per share or greater. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement, and Nasdaq now considers this matter closed. https://lnkd.in/ge-zejaG
-
Our latest press release has been featured on BioSpace, the leading digital hub for life science news! The article highlights the launch of our TR8™ PGx for Pre-emptive Oncology Care testing service to enhance patient safety when using fluoropyrimidine-based cancer therapeutics. Approximately 1 in 1,000 patients carry two copies of a variant in the DPYD gene, resulting in the absence of the DPD enzyme necessary to metabolize fluoropyrimidines, specifically capecitabine (branded Xeloda) and fluorouracil (5-FU), two chemotherapy drugs that are widely used as part of the standard of care treatment for patients with certain cancers. Potentially poor or intermediate metabolizers of these two medications due to DPD enzyme deficiencies and risk drug overexposure and the potential to experience severe, and at times fatal, toxicities when taking them. Between 3 percent and 8 percent of the general population has one copy of a variant associated with lower levels of the DPD enzyme, showing up more frequently in African Americans We’re proud to be contributing to the future of precision oncology care! #Pharmacogenomics #Oncology #GeneticTesting #TR8PGx #MolecularDiagnostics #PrecisionOncology #DPYD https://lnkd.in/eXYPWyfU
-
Our TR8™ PGx panel was designed to offer clinicians a tool to personalize treatment and reduce toxicity risks from 5-FU and capecitabine. 🧾 Read the announcement: https://lnkd.in/eZR5PBgr #Pharmacogenomics #Oncology #GeneticTesting #TR8PGx #MolecularDiagnostics #PrecisionOncology #DPYD #CancerSafety #AppliedDNA
-
mRNA-based personalized cancer vaccines are coming! At LineaRx, Inc., we're driving innovation with our LineaDNA™ and LineaIVT™ based solutions to accelerate the production of the next generation of personalized mRNA therapies through our GMP production of cell-free IVT templates and proprietary LineaRNAP™. Why LineaDNA and LineaIVT? Faster Production - Unlike plasmid-based methods, LineaDNA eliminates the need for bacterial amplification, reducing production timelines. Scalability - Enables efficient, high-yield production of DNA, meeting the growing demand for critical starting materials for personalized mRNA vaccines. Purity and Safety - No unwanted bacterial sequences or antibiotic resistance genes, reducing regulatory concerns and improving vaccine safety. Precision - Designed for seamless in vitro transcription, ensuring optimal mRNA synthesis for robust immune responses. Reduced dsRNA – LineaIVT greatly reduces dsRNA contamination while producing high mRNA yields, improving safety and reducing manufacturing timelines. #CancerImmunotherapy #PersonalizedMedicine #LineaDNA #mRNA #BiotechInnovation #CancerVaccines #AppliedDNA #FutureOfHealthcare #LineaRx #dsRNA https://lnkd.in/eTySB5VM
-
Applied DNA Clinical Labs (ADCL) has submitted a validation package to the New York State Department of Health (NYSDOH) for our Linea™ Avian Influenza H5 Dx (AIH5 Dx) assay. This PCR-based diagnostic is designed to detect and subtype H5 highly pathogenic avian flu — a pressing threat with growing concern in both animal and human health. Amidst rising cases and urgent CDC advisories, our team remains committed to delivering rapid, reliable solutions for emerging health crises. “Subject to NYSDOH approval, ADCL stands ready to empower physician and patient access to testing nationwide using our existing assets and workflows.” said James Hayward, Ph.D. #MolecularDiagnostics #PublicHealth #AvianInfluenza #H5N1 #PCRTesting #BiotechNews #AppliedDNA #InfectiousDisease #LDT #HealthcareInnovation #EpidemicPreparedness #DiagnosticDevelopment #Genomics #LaboratoryTesting #CLIAcertified https://lnkd.in/eFis9C69
-
We're ready! The 2nd Annual DNA Process Development & Manufacturing Summit starts tomorrow in Boston, MA. Don’t miss our poster presentation, ‘Fast-tracking mRNA Medicines: A synthetic DNA platform to optimize mRNA production’: Tuesday, March 26 at 3:30pm #syntheticbiology #EnzymaticDNAProduction #PCR #mRNA #GeneticMedicine #NucleicAcidBasedTherapies #DNAInnovation #CellFreeDNAProduction #SyntheticDNA #BiotechInnovation
-
-
LineaRx is gearing up to exhibit at the upcoming DNA Process Development & Manufacturing Summit, in Boston, MA starting next Tuesday, March 26. We are excited to showcase our Linea™ IVT and Linea™ DNA platforms. Stop by our booth or visit lineadna.com to learn more! #syntheticbiology #EnzymaticDNAProduction #PCR #mRNA #GeneticMedicine #NucleicAcidBasedTherapies #DNAInnovation #CellFreeDNAProduction #SyntheticDNA #BiotechInnovation
-